Intravenous immunoglobulin for Guillain-Barré syndrome

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 9, 2014, Pages

  Hughes, Richard A C ^a   Swan, Anthony V ^a   van Doorn, Pieter A ^b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; FUNCTIONAL STATUS ASSESSMENT; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOADSORPTION; MORBIDITY; MORTALITY; PLASMA EXCHANGE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SIDE EFFECT; SYSTEMATIC REVIEW; TIME TO TREATMENT; TREATMENT OUTCOME; ADULT; ADVERSE EFFECTS; CHILD; COMPARATIVE STUDY; CONVALESCENCE; GUILLAIN-BARRE SYNDROME; IMMUNOLOGY; META ANALYSIS; OUTCOME ASSESSMENT; PLASMAPHERESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; CHILD; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; OUTCOME ASSESSMENT (HEALTH CARE); PLASMA EXCHANGE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOVERY OF FUNCTION;

EID: 84919491002     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD002063.pub6     Document Type: Review

References (88)

1. Bril V, Ilse WK, Pearce R, Dhanani A, Sutton D, Kong K. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology 1996;46(1):100-3. [PUBMED: 8559353]
2. Diener HC, Haupt WF, Kloss TM, Rosenow F, Philipp T, Koeppen S, et al. A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune absorption in Guillain-Barré syndrome. European Neurology 2001;46(2):107-9. [PUBMED: 11528165]
3. El-Bayoumi MA, El-Refaey AM, Abdelkader AM, El-Assmy MM, Alwakeel AA, El-Tahan HM. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barré syndrome: a randomized study. Critical Care (London, England) 2011;15(4):R164. [PUBMED: 21745374]
4. Gürses N, Uysal S, Çetinkaya F, Íslek Í, Kalayci AG. Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Scandinavian Journal of Infectious Diseases 1995;27(3):241-3. [PUBMED: 8539548]
5. Haupt WF, Birkmann C, van der Ven C, Pawlik G. Apheresis and selective adsorption plus immunoglobulin treatment in Guillain-Barré syndrome. Therapeutic Apheresis 2000;4(3):198-200.
6. Haupt WF, Rosenow F, van der Ven C, Borberg H, Pawlik G. Sequential treatment of Guillain-Barré syndrome with extracorporeal elimination and intravenous immunoglobulin. Journal of the Neurological Sciences 1996;137(2):145-9. [PUBMED: 8782169]
7. Haupt WF, Rosenow F, van der Ven C, Borberg H, Pawlik G. Sequential treatment of Guillain-Barré syndrome with extracorporeal elimination and intravenous immunoglobulin. Therapeutic Apheresis 1997;1(1):55-7. [PUBMED: 10225782]
8. Korinthenberg R, Schessl J, Kirschner J, Mönting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics 2005;116(1):8-14. [PUBMED: 15995024]
9. Korinthenberg RK, Schessl J, Kirschner J. Prospective multicentre study on treatment of Guillain-Barré syndrome with high-dose immunoglobulins. Neuromuscular Disorders 2002;12:724.
10. Korinthenberg R, Schessl J, Kirschner J, Monting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics 2005;116(1):8-14. [PUBMED: 15995024]
11. Korinthenberg RK, Schessl J, Kirschner J. Prospective multicentre study on treatment of Guillain-Barré syndrome with high-dose immunoglobulins. Neuromuscular Disorders 2002;12:724.
12. Nomura K, Hamaguchi K, Hosokawa T, Hattori T, Satou T, Mannen T, et al. A randomized controlled trial comparing intravenous immunoglobulin and plasmapheresis in Guillain-Barré syndrome. Neurological Therapeutics 2001;18(1):69-81.
13. PSGBS Study Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997;349(9047):225-30. [PUBMED: 9014908]
14. Raphael J-C, Chevret S, Harboun M, Jars-Guincestre M-C, French Guillain-Barré syndrome Study Group. Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days. Journal of Neurology, Neurosurgery and Psychiatry 2001;71(2):235-8. [PUBMED: 11459901]
15. Raphaël JC, Harboun M, Bolgert F, Groupe Coopératif d'étude sur le SGB. Comparison of two doses of immunoglobulin for patients with GBS and contraindications to plasma exchange [Comparaison de deux posologies d'immunoglobulines (IgIV) chez les patients présentant un syndrome de Guillain-Barré (SGB) et des contre-indications aux échanges plasmatiques. Résultants de la premiere analyse intermédiare]. Réanimation Urgences 1998;7(Suppl 1):135s.
16. van der Meché FGA, Schmitz PIM, Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. New England Journal of Medicine 1992;326(17):1123-9. [PUBMED: 1552913]
17. Wang R, Feng A, Sun W, Wen Z. Intravenous immunoglobulin therapy in children with Guillain-Barré syndrome. Journal of Applied Clinical Pediatrics 2001;16(4):223-4. [DOI: cnki:ISSN:1003-515X.0.2001-04-029]
18. Fasanaro AM, Pizza V, Stella L. Plasma exchange and IV immunoglobulins: new approaches to the treatment of Guillain-Barré syndrome. Acta Neurologica (Napoli) 1992;47(4-6):369-80.
19. Horstkotte D, Kutkuhn B, Schultheiss HP, Strauer BE. Prophylactic use of human Ig-GAM-preparations in patients on mechanical ventilation undergoing plasmapheresis: results of a randomized study [Prophylaktischer Einsatz humaner Ig-GAM-Konzentrate bei Patienten mit Plasmaseparation unter Respiratortherapie: Ergebnisse einer randomisierten Studie]. Intensivmedizin und Notfallmedizin 1992;29(5):227-33.
20. Hosokawa T, Hamaguchi K, Tomioka R, Tsuji T, Nomura K, Ohno R, et al. Comparative study of efficacy of plasma exchange versus intravenous gammaglobulin treatment on acute postinfectious polyradiculoneuropathy: a preliminary report. Therapeutic Apheresis 1998;2(4):288-91.
21. Kanra G, Ozon A, Vajsar J, Castagna L, Secmeer G, Topaloglu H. Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. European Journal of Paediatric Neurology 1997;1:7-12.
22. Koul R, Chacko A, Ahmed R, Varghese T, Javed H, Al Lamki Z. Ten-year prospective study (clinical spectrum) of childhood Guillain-Barré syndrome in the Arabian peninsula: comparison of outcome in patients in the pre-and post-intravenous immunoglobulin eras. Journal of Child Neurology 2003;18(11):767-71.
23. Kuwabara S, Mori M, Ogawara K, Hattori T, Oda S, Koga M. Intravenous immunoglobulin therapy for Guillain-Barré syndrome. Muscle & Nerve 2001;24(1):54-8.
24. Ravasio A, Pasquinelli M, Currò Dossi B, Neri W, Guidi C, Gessaroli M, et al. Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology. High dose intravenous immune globulins and plasma exchange in Guillain-Barré syndrome. Italian Journal of Neurological Sciences 1995;16(7):487-92.
25. Reisin RC, Pociecha J, Rodriguez E, Massaro ME, Arroyo HA, Fejerman N. Severe Guillain-Barré syndrome in childhood treated with human immune globulin. Paediatric Neurology 1996;14(4):308-12.
26. Yélamos AM, Vilanueva MH, Plana MO, Homs JM, Catafau JS, Martinez-Matos JA. Treatment of Guillain-Barré syndrome: immunoglobulins or plasmapheresis [Tratiamento del sindrome de Guillain-Barré: immunoglobulinas o plasmaféresis]. Neurologia 1998;13(4):166-9.
27. van Doorn PA. What's new in Guillain-Barré syndrome 2007-2008. Journal of the Peripheral Nervous System 2009;14(2):72-4.
28. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Annals of Neurology 1990;27 Suppl:S21-4.
29. Bernsen RA, de Jager AE, Schmitz PI, van der Meché FG. Residual physical outcome and daily living 3 to 6 years after Guillain-Barré syndrome. Neurology 1999;53(2):409-10.
30. Bertorini TE, Nance AM, Horner LH, Greene W, Gelfand MS, Jaster JH. Complications of intravenous gammaglobulin in neuromuscular and other diseases. Muscle & Nerve 1996;19(3):388-91.
31. Bick S, Tschernatsch M, Karg A, Fuehlhuber V, Trenczek TE, Faltermeier K, et al. Intravenous immunoglobulin inhibits BAFF production in chronic inflammatory demyelinating polyneuropathy -a new mechanism of action?. Journal of Neuroimmunology 2013;256(1-2):84-90.
32. Casteels-van Daele M, Wijndaele L, Brock P, Kruger M. Aseptic meningitis associated with high dose intravenous immunoglobulin therapy. Journal of Neurology, Neurosurgery & Psychiatry 1992;55(10):980-1.
33. Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacology & Therapeutics 2004;102(3):177-93.
34. Dawson WB, Phillips LH 2nd. A comparison between IVIg and plasma exchange in Guillain-Barré syndrome: a review and decision analysis of the two treatment modalities. Clinical Neuropharmacology 1997;18(5):377-90.
35. Eijkhout HW, van Aken WG. 33 Blood, blood components, plasma and plasma products. In: Aronson JK editor(s). Side Effects of Drugs Annual. 14th Edition. Amsterdam: Elsevier, 2002.
36. Farcas P, Avnun L, Frisher S, Herishanu YO, Wirguin I. Efficacy of a repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome. Lancet 1997;350(9093):1747.
37. French Co-operative Group on Plasma Exchange in Guillain-Barré Syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Annals of Neurology 1987;22(6):753-61.
38. French Co-operative Group on Plasma Exchange in Guillain-Barré Syndrome. Plasma exchange in Guillan-Barré syndrome: one-year follow-up. Annals of Neurology 1992;32(1):94-7.
39. French Co-operative Group on Plasma Exchange in Guillain-Barré Syndrome. Appropriate number of plasma exchanges in Guillain-Barré syndrome. Annals of Neurology 1997;41(3):298-306.
40. The Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985;35(8):1096-104.
41. Greenwood RJ, Newsom Davis J, Hughes RA, Aslan S, Bowden AN, Chadwick DW, et al. Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984;1(8382):877-9.
42. Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. The Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Annals of Neurology 1998;44(5):780-8.
43. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
44. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial of prednisolone in acute polyneuropathy. Lancet 1978;2(8093):750-3.
45. Hughes RAC, Cornblath DR. Guillain-Barré syndrome. Lancet 2005;366(9497):1653-66.
46. Hughes RA, Swan AV, Raphael JC, Annane D, van Koningsveld R, van Doorn PA. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 2007;130(Pt 9):2245-57.
47. Hughes RA, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2012, Issue 8. [DOI: 10.1002/14651858.CD001446.pub4]
48. Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, et al. High dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura. Lancet 1981;1(8232):1228-31.
49. The Italian Guillain-Barré Group. The prognosis and main prognostic indicators of Guillain-Barré syndrome: a multicentre prospective study of 297 patients. Brain 1996;119(Pt 6):2053-61.
50. Jacobs BC, van Doorn PA, Schmitz P, Tio-Gillen A, Herbrink P, Visser LH, et al. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Annals of Neurology 1996;40(2):181-7.
51. Kleyweg RP, van der Meché FGA, Meulstee J. Treatment of Guillain-Barré syndrome with high dose gammaglobulin. Neurology 1988;38(10):1639-41.
52. Kleyweg RP, van der Meché FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle & Nerve 1991;14(11):1103-9.
53. Koch C. Blood, blood components, plasma and plasma products. In: Dukes MNG, Aronson JR editor(s). Meyler's Side Effects of Drugs. 14. Amsterdam: Elsevier, 2000.
54. Kuitwaard K, de Gelder J, Tio-Gillen AP, Hop WC, van Gelder T, van Toorenenbergen AW, et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Annals of Neurology 2009;66(5):597-603.
55. Kuwabara S, Mori M, Ogawara K, Hattori T, Yuki N. Indicators of rapid clinical recovery in Guillain-Barré syndrome. Journal of Neurology, Neurosurgery & Psychiatry 2001;70(4):560-2.
56. Levy JB, Pusey CD. Nephrotoxicity of intravenous immunoglobulin. Quarterly Journal of Medicine 2000;93(11):751-5.
57. Llewelyn CA, Hewitt PE, Knight RS, Amar K, Cousens S, Mackenzie J, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004;363(9407):417-21.
58. McCluskey DR, Boyd NA. Anaphylaxis with intravenous gammaglobulin. Lancet 1990;336(8719):874.
59. Merkies IS, Schmitz PI, Samijn JP, van der Meché FG, van Doorn PA. Fatigue in immune-mediated polyneuropathies. Neurology 1999;53(8):1648-54.
60. Nagpal S, Benstead T, Shumak K, Rock G, Brown M, Anderson DR. Treatment of Guillain-Barré syndrome: a cost-effectiveness analysis. Journal of Clinical Apheresis 1999;14:107-13.
61. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New England Journal of Medicine 1991;324(23):1633-9.
62. NIH Consensus Development. The utility of therapeutic plasmapheresis for neurological disorders. JAMA 1986;256(10):1333-7.
63. Osterman PO, Lundemo G, Pirskanen R, Fagius J, Pihlstedt P, Siden A, et al. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984;2(8415):1296-9.
64. Rajabally YA, Uncini A. Outcome and its predictors in Guillain-Barre syndrome. Journal of Neurology, Neurosurgery & Psychiatry 2012;83(7):711-8.
65. Raphael JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2012, Issue 7. [DOI: 10.1002/14651858.CD001798.pub2]
66. Rees JH, Thompson RD, Smeeton NC, Hughes RA. Epidemiological study of Guillain-Barré syndrome in south east England. Journal of Neurology, Neurosurgery & Psychiatry 1998;64(1):74-7.
67. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
68. Rinaldi S. Update on Guillain-Barre syndrome. Journal of the Peripheral Nervous System 2013;18(2):99-112.
69. Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, et al. Guillain-Barre syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011;29(3):599-612.
70. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Annals of Internal Medicine 1994;121(4):259-62.
71. Tackenberg B, Jelcic I, Baerenwaldt A, Oertel WH, Sommer N, Nimmerjahn F, et al. Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proceedings of the National Academy of Sciences of the United States of America 2009;106(12):4788-92.
72. Tan E, Hajinazarian M, Bay W, Neff J, Mendell JR. Acute renal failure resulting from intravenous immunoglobulin therapy. Archives of Neurology 1993;50(2):137-9.
73. Tsai CP, Wang KC, Liu CY, Sheng WY, Lee TC. Pharmacoeconomics of therapy for Guillain-Barré syndrome: plasma exchange and intravenous immunoglobulin. Journal of Clinical Neuroscience 2007;14(7):625-9.
74. van Koningsveld R, Schmitz PIM, van der Meché FGA, Visser LH, Meulstee J, van Doorn PA, Dutch GBS Study Group. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 2004;363:192-6.
75. van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, Jacobs BC. A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurology 2007;6(7):589-94.
76. van Nes SI, Vanhoutte EK, van Doorn PA, Hermans M, Bakkers M, Kuitwaard K, et al. Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Clinical & Vaccine Immunology: CVI 2011;76(4):337-45.
77. Vanhoutte EK, Faber CG, van Nes SI, Jacobs BC, van Doorn PA, van Koningsveld R, et al. Modifying the Medical Research Council grading system through Rasch analyses. Brain 2012;135(Pt 5):1639-49.
78. Vermeulen M, van der Meché FGA, Speelman JD, Weber A, Busch HFM. Plasma and gammaglobulin infusion in chronic inflammatory polyneuropathy. Journal of the Neurological Sciences 1985;70(3):317-26.
79. Whittam LR, Hay RJ, Hughes RA. Eczematous reactions to human immune globulin. British Journal of Dermatology 1997;137(3):481-2.
80. Winters JL, Brown D, Hazard E, Chainani A, Andrzejewski C Jr. Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome. BMC Health Services Research 2011;11:101-9.
81. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. New England Journal of Medicine 1999;340(3):227-8.
82. Yuki N, Ang CW, Koga M, Jacobs BC, van Doorn PA, Hirata K, et al. Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside. Annals of Neurology 2000;47(3):314-21.
83. Yuki N, Hartung HP. Guillain-Barré syndrome. New England Journal of Medicine 2012;366(24):2294-304.
84. Hughes R, Raphaël J, Swan A, van Doorn P. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2000, Issue unknown. [DOI: 10.1002/14651858.CD002063]
85. Hughes RAC, Raphaël JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD002063.pub2]
86. Hughes RAC, Raphaël JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD002063.pub3]
87. Hughes RAC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2010, Issue 6. [DOI: 10.1002/14651858.CD002063.pub4]
88. Hughes RAC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2012, Issue 7. [DOI: 10.1002/14651858.CD002063.pub5]